Connection

Co-Authors

This is a "connection" page, showing publications co-authored by AGDA KARINA B. ETEROVIC and GORDON B MILLS.
Connection Strength

1.415
  1. Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion. Eur J Cancer. 2019 10; 120:54-64.
    View in: PubMed
    Score: 0.174
  2. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Sci Transl Med. 2017 05 31; 9(392).
    View in: PubMed
    Score: 0.149
  3. A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst. 2015 Jul; 107(7).
    View in: PubMed
    Score: 0.128
  4. Clinical actionability enhanced through deep targeted sequencing of solid tumors. Clin Chem. 2015 Mar; 61(3):544-53.
    View in: PubMed
    Score: 0.127
  5. The impact of tumor heterogeneity on patient treatment decisions. Clin Chem. 2013 Jan; 59(1):38-40.
    View in: PubMed
    Score: 0.054
  6. Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. Cell Rep. 2020 04 14; 31(2):107502.
    View in: PubMed
    Score: 0.045
  7. Correction: A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. Oncotarget. 2019 Aug 27; 10(50):5254.
    View in: PubMed
    Score: 0.044
  8. Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases. Breast Cancer Res Treat. 2019 Nov; 178(2):251-261.
    View in: PubMed
    Score: 0.043
  9. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res. 2019 07 05; 21(1):78.
    View in: PubMed
    Score: 0.043
  10. Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations. JCO Precis Oncol. 2019; 3.
    View in: PubMed
    Score: 0.042
  11. Prospective Clinical Sequencing of Adult Glioma. Mol Cancer Ther. 2019 05; 18(5):991-1000.
    View in: PubMed
    Score: 0.042
  12. Molecular determinants of post-mastectomy breast cancer recurrence. NPJ Breast Cancer. 2018; 4:34.
    View in: PubMed
    Score: 0.041
  13. Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer. JCO Precis Oncol. 2018; 2018.
    View in: PubMed
    Score: 0.040
  14. A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. Clin Cancer Res. 2017 Nov 01; 23(21):6468-6477.
    View in: PubMed
    Score: 0.038
  15. A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. Oncotarget. 2017 Jun 27; 8(26):41806-41814.
    View in: PubMed
    Score: 0.037
  16. Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers. Genome Res. 2017 07; 27(7):1112-1125.
    View in: PubMed
    Score: 0.037
  17. Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. Cancer Cell. 2017 02 13; 31(2):225-239.
    View in: PubMed
    Score: 0.037
  18. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med. 2016 10 25; 14(1):168.
    View in: PubMed
    Score: 0.036
  19. The degree of intratumor mutational heterogeneity varies by primary tumor sub-site. Oncotarget. 2016 May 10; 7(19):27185-98.
    View in: PubMed
    Score: 0.035
  20. Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS One. 2016; 11(3):e0151121.
    View in: PubMed
    Score: 0.034
  21. The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. Cancer Cell. 2015 Oct 12; 28(4):515-528.
    View in: PubMed
    Score: 0.033
  22. Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS One. 2015; 10(9):e0136851.
    View in: PubMed
    Score: 0.033
  23. Functional consequence of the MET-T1010I polymorphism in breast cancer. Oncotarget. 2015 Feb 20; 6(5):2604-14.
    View in: PubMed
    Score: 0.032
  24. Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors. Oncotarget. 2014 Sep 30; 5(18):8544-57.
    View in: PubMed
    Score: 0.031
  25. Bias from removing read duplication in ultra-deep sequencing experiments. Bioinformatics. 2014 04 15; 30(8):1073-1080.
    View in: PubMed
    Score: 0.029
  26. Molecular characterization of gallbladder cancer using somatic mutation profiling. Hum Pathol. 2014 Apr; 45(4):701-8.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.